About Us
Edward HuCo-CEO of Wuxi apptec
Aaron Yu
Managing Director at
Investment Department of Fosun Pharma
Mark EngelCEO
of Phagelux
CEO of Phagelux
We are initially focused ion topical AMR infections since (a) the size of the market is so large and (b) there are virtually no other affordable solutions, either on the market or under development, to treat or prevent such infections at a reasonable cost. However, over time, in addition to our eczema and acne treatments, we will look to in-license later stage biological dermatological treatments for some underserved indications including for the following problems: additional AMR topical solutions, oncodermatology, actinic keratosis, and/or psoriasis. As we expand we will become one of the leading skin sciences companies in China.
Mark Engel
CEO
Previously founded 4 successful life sciences companies
Dr. Nancy Tawil
Chief Scientific Officer
Ph.D in Biomedical Engineering and Phage Expert
Dr. Assaf Raz
Lab Manager - Wuhan
Ph.D in Biology and Leading Global Lysin Expert
Sandy Li
Quality Manager
M.S. in Chemistry. Experienced in GMP
drug production
Dr. Iness Hammami
Vice-President, Research
Ph.D in Chemical Engineering.
10 years of experience in biopharmaceutical engineering